Breast cancerOvarian cancerLung cancerGastric cancer Liver cancerPan-cancerBreast cancer Breast cancerLiver cancerPan-cancer Breast cancer Custom Pan-cancer DNA Immunotherapy
Plot options
2. Select dataset: Compare
METABRIC: long follow-up (median: 94 months), average characteristics (78% ER positive, 12% HER2 positive), treatment data available for this dataset only! TCGA: very short follow-up (median only 25 months), no grade. GSE40267: almost exclusively ER negative patients (92%). GSE19783: nodal status not available, 38% ER negative, high proportion of HER2 positive patients (18%).
n = number of patients with available clinical data
Please note: the generated p value does not include correction for multiple hypothesis testing by default.
Please kindly cite our paper to support further development: Lanczky A, Nagy A, Bottai G, Munkacsy G, Paladini L, Szabo A, Santarpia L, Gyorffy B. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2,178 breast cancer patients, Breast Cancer Res Treat. 2016;160(3):439-446.
KMplot.com Copyright © 2009-2022 | Contact | Sitemap